EP1517896A2 - Phenyl- und pyridyl-diazaheterocyclen mit einer tnf modulierenden wirkung - Google Patents

Phenyl- und pyridyl-diazaheterocyclen mit einer tnf modulierenden wirkung

Info

Publication number
EP1517896A2
EP1517896A2 EP03760042A EP03760042A EP1517896A2 EP 1517896 A2 EP1517896 A2 EP 1517896A2 EP 03760042 A EP03760042 A EP 03760042A EP 03760042 A EP03760042 A EP 03760042A EP 1517896 A2 EP1517896 A2 EP 1517896A2
Authority
EP
European Patent Office
Prior art keywords
formula
compound
group
solvates
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03760042A
Other languages
English (en)
French (fr)
Inventor
Marco Baroni
Bernard Bourrie
Pierre Casellas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of EP1517896A2 publication Critical patent/EP1517896A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention relates to new phenyl- and pyridyldiazaheterocycles having TNF modulating activity, the pharmaceutical compositions containing them and a process for their preparation.
  • US3, 188,313 describes piperazines substituted by an indolyl-alkyl radical showing activity on the central nervous system, on the cardiovascular system and on the muscular and bone systems.
  • WO01 / 29026 describes certain tetrahydro-pyridines, substituted by a quinolinyl-alkyl or isoquinolyl-alkyl radical with activity on the modulation of TNF-alpha (from the English Tumor Necrosis Factor).
  • TNF-alpha is a cytokine which has recently aroused interest as a mediator of immunity, inflammation, cell proliferation, fibrosis etc. This mediator is abundantly present in inflamed synovial tissue and plays an important role in the pathogenesis of autoimmunity
  • diazaheterocycles carrying a quinolinyl-alkyl or isoquinolyl-alkyl radical have a potent activity with respect to the modulation of TNF-alpha.
  • the present invention relates, according to one of its aspects, to diazaheterocycles of formula (I):
  • X represents N or CH
  • Ri represents a hydrogen or halogen atom or a group CF 3 ;
  • R 2 and R 3 independently represent a hydrogen atom or a methyl group; n is 0 or 1;
  • W represents a diazoheterocycle of formula (a) to (d)
  • (e) (f) or 4 represents a hydrogen or halogen atom, a (C ⁇ -C) alkyl group, a CF 3 group, an ino group, mono (C ⁇ - C 4 ) alkylamino, di (C ⁇ -C) alkylamino;
  • R 5 represents a hydrogen or halogen atom, a group
  • (C ⁇ -C) alkyl denotes a monovalent radical of a saturated C ⁇ -C 4 straight chain or branched hydrocarbon.
  • halogen denotes an atom chosen from chlorine, bromine, iodine and fluorine.
  • the quinoline and isoquinoline rings can be attached to the rest of the molecule of formula (I) by any of the carbon atoms at positions 6 or 7.
  • Des Preferred compounds of formula (I) are those where n is zero.
  • Other preferred compounds are those where R 2 and R 3 are each a hydrogen atom.
  • Ri is a group CF 3 .
  • Other preferred compounds are those where Ri is a fluorine or chlorine atom.
  • the compounds of formula (I) can exist as N-oxide derivatives.
  • the compounds of formula (I) can in particular carry one or two N-oxide groups on the diazoheterocycles (a) to (d) and / or an N-oxide group on the quinoline or the isoquinoline of the group A.
  • the above three nitrogen can all be oxidized, compounds bearing one or two N-oxide groups, one on the diazoheterocycle and the other on quinoline or isoquinoline, are preferred.
  • the salts of the compounds of formula (I) according to the present invention also include the addition salts with pharmaceutically acceptable inorganic or organic acids such as the hydrochloride, the hydrobromide, the sulfate, the hydrogen sulfate, the dihydrogen phosphate, the citrate, maleate, tartrate, fumarate, gluconate, methanesulfonate, 2-naphthalenesulfonate, etc., than addition salts which allow proper separation or crystallization of the compounds of formula (I), such as picrate, oxalate or addition salts with optically active acids, for example camphosulfonic acids and mandelic or substituted mandelic acids.
  • the compounds of formula (I) can be synthesized by a process which provides for a condensation / reduction reaction starting from a compound of formula (II): in which X, W and Ri are as defined above, with an aldehyde of formula (III):
  • the condensation reaction is normally carried out by mixing the starting compounds (II) and (IV) in an inert organic solvent, according to conventional methods.
  • inert organic solvent a solvent which does not interfere with the reaction.
  • solvents are, for example, alcohols such as methanol, ethanol, isopropanol or butanol.
  • leaving group L it is possible, for example, to use a chlorine or bromine atom or else a mesyloxy group (CH 3 -SO -O-).
  • the reaction is carried out at a temperature between -10 ° C. and the reflux temperature of the reaction mixture, the reflux temperature being preferred.
  • the reaction can be suitably carried out in the presence of a proton acceptor, for example an alkali carbonate or a tertiary amine such as triethylamine.
  • a proton acceptor for example an alkali carbonate or a tertiary amine such as triethylamine.
  • the reaction is normally completed after a few hours, normally 1 to 6 hours are sufficient to complete the condensation.
  • the desired compound of formula (I) is isolated according to conventional techniques in the form of the free base or one of its salts.
  • the free base can be transformed into one of its salts by simple salification in an organic solvent such as an alcohol, preferably ethanol or isopropanol, an ether such as 1,2-dimethoxyethane, ethyl acetate , acetone or a hydrocarbon such as hexane.
  • the starting compounds of formula (II) containing a diazotized nucleus (a) or (d) are known or they can be prepared in a similar manner to the known compounds.
  • the starting compounds of formula (II) in which the diazotized nucleus is (b) or (c) and X is N are also known or else they can be prepared in a similar manner to the known compounds, as described for example in J. Med . Chem., 1998, 41, 674-681.
  • X and CH can be prepared by reaction of an optionally substituted bromo-benzene with the nucleus (b) or (c), the nitrogen not having to take part in the reaction being suitably protected beforehand. Examples of such a reaction are given in the experimental part.
  • W represents a group of formula (b) or (c) above are new and represent another aspect of the present invention.
  • the compounds of formulas (III) and (IV) are known and can be prepared in a similar manner to the known compounds, for example as described in WO01 / 29026.
  • the compounds of formula (I) carrying an N-oxide group on the nitrogen atom of the quinoline or of the isoquinoline can be prepared from the N-oxide derivatives of the compounds of formula (III).
  • the compounds of formula (I) carrying an N-oxide group on the nitrogen atoms of the rings (a) to (d) can be prepared by oxidation of the corresponding compounds of formula (I).
  • the compound of formula (I) as obtained by the above syntheses is subjected to an oxidation reaction according to conventional methods, for example to a reaction with m-chloro-perbenzoic acid in a suitable solvent and isolated according to the usual techniques well known to those skilled in the art.
  • the compounds of the invention have advantageous properties with respect to the inhibition of TNF- ⁇ .
  • LPS lipopolysaccharide
  • test products are administered orally to groups of 5 female Balb / c mice (Charles River, France) aged 7 to 8 weeks.
  • the LPS is administered intravenously (10 ⁇ g / mouse).
  • the blood of each animal is taken 1.5 hours after administration of the LPS.
  • the samples are centrifuged, the plasma is recovered and frozen at -80 ° C.
  • TNF- ⁇ is measured using commercial kits (R&D, Abingdon, UK).
  • the compounds of. formula (I) and its salts or solvates may well be used in the treatment of diseases linked to immune and inflammatory disorders or as analgesics.
  • the compounds of formula (I) can be used to treat atherosclerosis, autoimmune diseases, diseases which cause demyelination of neurons (such as multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases , idiopathic pulmonary fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout, bone and cartilage resorption, osteoporosis, Paget's disease, multiple myioma, uveoretinitis, septic shock, sepsis, endotoxin shock, graft versus host reaction, transplant rejection, adult respiratory distress syndrome, silicosis, asbestosis, pulmonary sarcoidosis, Crohn's disease
  • the compounds of formula (I) and their pharmaceutically acceptable salts and solvates are preferably administered orally.
  • the active principle can be administered in unit administration forms, in admixture with conventional pharmaceutical carriers, to animals and humans for the treatment of the abovementioned conditions.
  • Suitable unit dosage forms include, for example, possibly scored tablets, capsules, powders, granules and oral solutions or suspensions.
  • the main active ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
  • the tablets can be coated with sucrose or other suitable materials or else they can be treated in such a way that they have a prolonged or delayed activity and that they continuously release a predetermined quantity of active principle.
  • a preparation in capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard capsules.
  • a preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
  • Water dispersible powders or granules may contain the active ingredient in admixture with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or correctors taste.
  • the active principle can also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
  • the active principle can also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters.
  • the amount of active ingredient to be administered depends as always on the degree of progression of the disease as well as on the age and weight of the patient.
  • the unit doses generally comprise from 0.001 to 100 mg, better still from 0.01 to 50 mg, preferably from 0.1 to 20 mg of active principle, advantageously from 0.5 to 10 mg.
  • the present invention relates to a combination comprising a compound of formula (I) or one of its pharmaceutically acceptable salts or solvates, and at least one compound chosen from immunosuppressive agents, such as interferon beta -lb; adrenocorticotropic hormone; glucocorticoids such as prednisone or methylprednisolone; interleukin-1 inhibitors.
  • immunosuppressive agents such as interferon beta -lb; adrenocorticotropic hormone; glucocorticoids such as prednisone or methylprednisolone; interleukin-1 inhibitors.
  • the compounds of the invention can be combined with a compound chosen from roquinimex (1,2-dihydro-4-hydroxy-N, l-dimethyl l-2-oxo-3 -quinolinecarboxanilide), myloran (product from the company Autoimmune containing bovine myelin), the antegren (human monoclonal antibody from the companies Elan / Athena Neurosciences) the interferon beta-lb recombinant.
  • roquinimex 1,2-dihydro-4-hydroxy-N, l-dimethyl l-2-oxo-3 -quinolinecarboxanilide
  • myloran product from the company Autoimmune containing bovine myelin
  • the antegren human monoclonal antibody from the companies Elan / Athena Neurosciences
  • the interferon beta-lb recombinant the interferon beta-lb recombinant.
  • the invention relates to a method of treatment of diseases linked to immune and inflammatory disorders.
  • autoimmune diseases diseases that cause demyelination of neurons (such as multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases, fibrosis idiopathic pulmonary, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout, bone and cartilage resorption, osteoporosis, Paget's disease, multiple myeloma, uveoretinitis, septic shock, septicemia, endotoxin shock, graft versus host reaction, transplant rejection, adult respiratory distress syndrome, silicosis, asbestosis, pulmonary sarcoidosis, Crohn's disease, ulcerative colitis, lateral sclerosis amyotrophic, Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, hemodynamic shock, ischemic pathologies (myocardi
  • the compounds of Examples 3 to 9 are prepared by following the procedures described in Example 1.
  • the compounds of Examples 10 to 13 are prepared by following the procedures described in Example 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP03760042A 2002-06-18 2003-06-16 Phenyl- und pyridyl-diazaheterocyclen mit einer tnf modulierenden wirkung Withdrawn EP1517896A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207507A FR2840896B1 (fr) 2002-06-18 2002-06-18 Phenyl-et pyridyl-piperazines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR0207507 2002-06-18
PCT/FR2003/001813 WO2003106425A2 (fr) 2002-06-18 2003-06-16 Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf

Publications (1)

Publication Number Publication Date
EP1517896A2 true EP1517896A2 (de) 2005-03-30

Family

ID=29595360

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03760042A Withdrawn EP1517896A2 (de) 2002-06-18 2003-06-16 Phenyl- und pyridyl-diazaheterocyclen mit einer tnf modulierenden wirkung

Country Status (6)

Country Link
US (1) US20050209216A1 (de)
EP (1) EP1517896A2 (de)
JP (1) JP2005533790A (de)
AU (1) AU2003263237A1 (de)
FR (1) FR2840896B1 (de)
WO (1) WO2003106425A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (de) * 1959-09-25 1900-01-01
US4544657A (en) * 1983-05-19 1985-10-01 Hoffmann-La Roche Inc. Substituted isoquinolines
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
HK1046532B (zh) * 1999-10-22 2005-03-18 Sanofi-Aventis 具有抑制tnf活性的苯基-和吡啶基-四氫吡啶
FR2804430B1 (fr) * 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03106425A2 *

Also Published As

Publication number Publication date
FR2840896B1 (fr) 2005-04-08
WO2003106425A3 (fr) 2004-04-01
FR2840896A1 (fr) 2003-12-19
WO2003106425A2 (fr) 2003-12-24
AU2003263237A8 (en) 2003-12-31
US20050209216A1 (en) 2005-09-22
JP2005533790A (ja) 2005-11-10
AU2003263237A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2004099176A1 (fr) Derives de piperidinyl- et piperazinyl-alkylcarbamates, leurs procedes de preparation et leur application en therapeutique
EP1720872A1 (de) Aryl- und heteroarylpiperidincarboxylatderivate, deren herstellung und deren verwendung in form von faah-enzyminhibitoren
EP1708994B1 (de) Derivate vom aryloxyalkylcarbamat-typ, verfahren zu deren herstellung und deren verwendung in therapeutika
EP1248785B1 (de) Tetrahydropyridine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
EP1214313B1 (de) Heteroaryloxypropanolamine als beta3-adrenergischer rezeptor-agonisten
EP1438291B1 (de) Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
EP1226137B8 (de) Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung
EP1383762B1 (de) Tetrahydropyridyl-alkyl-heterozykle, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
EP1383761B1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
EP1517896A2 (de) Phenyl- und pyridyl-diazaheterocyclen mit einer tnf modulierenden wirkung
EP0950049B1 (de) Diphenylalkyl-tetrahydropyridine, verfahren zu ihren herstellung und diese enthaltende arzneimittel
EP1448550B1 (de) Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung
WO2000063170A1 (fr) Derives de cyclobutene-3,4-dione en tant qu'inhibiteurs de la phosphodiesterase 5
EP0266246A1 (de) Imidazo[4,5-b]pyridone-2-Derivate, ihre Herstellung und ihre Anwendung in der Heilkunde
FR2810984A1 (fr) Pyridyl-tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2823748A1 (fr) Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2800071A1 (fr) Tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1998003485A1 (fr) PHENOXYPROPANOLAMINES A ACTION ANTAGONISTE β3-ADRENERGIQUE
EP0695747A1 (de) Derivate von substituierten N-oxiden 1-(7-chlorochinolin-4-yl)pyrazol-3-carboxamiden als Ligand des neurotensin Rezeptors
FR2823750A1 (fr) Tetrahydropyridyl-alkyl-heterocycles, procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050118

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20050318

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050929